DK0703911T3 - Sekundære aminer som antidiabetiske og antiobesitetsmidler - Google Patents

Sekundære aminer som antidiabetiske og antiobesitetsmidler

Info

Publication number
DK0703911T3
DK0703911T3 DK94914531.2T DK94914531T DK0703911T3 DK 0703911 T3 DK0703911 T3 DK 0703911T3 DK 94914531 T DK94914531 T DK 94914531T DK 0703911 T3 DK0703911 T3 DK 0703911T3
Authority
DK
Denmark
Prior art keywords
pct
antiobesity agents
antidiabetic
date dec
secondary amines
Prior art date
Application number
DK94914531.2T
Other languages
English (en)
Inventor
Robert L Dow
Stephen W Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0703911T3 publication Critical patent/DK0703911T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94914531.2T 1993-06-14 1994-05-20 Sekundære aminer som antidiabetiske og antiobesitetsmidler DK0703911T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7602693A 1993-06-14 1993-06-14

Publications (1)

Publication Number Publication Date
DK0703911T3 true DK0703911T3 (da) 1997-10-06

Family

ID=22129472

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914531.2T DK0703911T3 (da) 1993-06-14 1994-05-20 Sekundære aminer som antidiabetiske og antiobesitetsmidler

Country Status (22)

Country Link
US (1) US5767133A (da)
EP (1) EP0703911B1 (da)
JP (1) JPH08506348A (da)
KR (1) KR960703120A (da)
CN (1) CN1129443A (da)
AT (1) ATE154935T1 (da)
AU (1) AU675536B2 (da)
BR (1) BR9406823A (da)
CA (1) CA2164009A1 (da)
CZ (1) CZ327795A3 (da)
DE (1) DE69404039T2 (da)
DK (1) DK0703911T3 (da)
ES (1) ES2104383T3 (da)
FI (1) FI942791A7 (da)
GR (1) GR3024134T3 (da)
HU (1) HUT70844A (da)
IL (1) IL109904A0 (da)
NO (1) NO955047L (da)
NZ (1) NZ265692A (da)
PL (1) PL312005A1 (da)
WO (1) WO1994029290A1 (da)
ZA (1) ZA944139B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
JPH11504649A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト
WO1996035670A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
GB2305665A (en) * 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
KR19990067172A (ko) * 1995-10-31 1999-08-16 디. 제이. 우드, 스피겔 알렌 제이 1-(2-ㄲ2-이속사졸-3-일벤조푸란-5-일옥시ㅒ에틸아미노)-3-페녹시-2(에스)-올의 제조 방법 및 중간체
JP3124242B2 (ja) 1996-01-10 2001-01-15 旭化成工業株式会社 新規な３環性化合物
WO1997025311A1 (en) * 1996-01-10 1997-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US6008361A (en) * 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
US6031105A (en) * 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
EP0822185A1 (en) * 1996-07-31 1998-02-04 Pfizer Inc. B-3-adrenergic agonists as antidiabetic and antiobesity agents
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
WO1998021184A1 (en) * 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
DK0842924T3 (da) * 1996-11-14 2003-12-08 Pfizer Pyridine intermediates, useful in the synthesis ofbeta-adrenergic receptor agonists
US6534496B1 (en) 1997-04-17 2003-03-18 Takeda Chemical Industries, Inc. Thermogenic composition and benzazepine thermogenics
AU735249B2 (en) 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US6469031B1 (en) 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) * 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
DK1040106T3 (da) * 1997-12-19 2002-12-02 Bayer Ag Carboxylsubstituerede chromanderivater til anvendelse som beta 3 adrenoreceptor-agonister
EP1077968A1 (en) * 1998-05-12 2001-02-28 American Home Products Corporation Naphtho[2,3-b]heteroar-4-yl derivatives
US6121271A (en) * 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
CA2361516A1 (en) * 1999-01-27 2000-08-03 Jeffrey Thomas Mullaney Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
US7045545B1 (en) 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
DE19932314A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
EP1238973A4 (en) * 1999-12-16 2003-01-22 Asahi Chemical Ind NEW SUBSTITUTED TRICYCLIC COMPOUNDS
WO2001083451A1 (en) * 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
WO2002100850A1 (en) * 2001-06-08 2002-12-19 Kuraray Co., Ltd. Processes for preparation of heterocyclic compounds
KR100816527B1 (ko) * 2001-09-12 2008-04-10 한국화학연구원 페닐테트라졸 유도체로 치환된 β-아미노알코올 화합물
EP1447400B1 (en) * 2001-10-25 2008-09-17 Asahi Kasei Pharma Corporation Bicyclic compound
EP1478625A1 (en) 2002-02-27 2004-11-24 Pfizer Products Inc. Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1407769A1 (en) * 2002-10-11 2004-04-14 Pfizer Limited Indole derivatives as beta-2 agonists
MXPA05003866A (es) * 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
US6844362B2 (en) 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
EP1581491A1 (en) * 2003-01-06 2005-10-05 Eli Lilly And Company Indole derivatives as ppar modulators
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
ATE406363T1 (de) 2003-05-09 2008-09-15 Hoffmann La Roche Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
JP2008100916A (ja) * 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
KR20110050733A (ko) 2008-10-09 2011-05-16 아사히 가세이 파마 가부시키가이샤 인다졸 유도체
AU2009301798B2 (en) 2008-10-09 2012-03-01 Asahi Kasei Pharma Corporation Indazole compound
US20100222404A1 (en) * 2008-11-04 2010-09-02 Asahi Kasei Pharma Corporation Indazole derivative dihydrochloride
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
CA2796877A1 (en) * 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
EP4161503A4 (en) 2020-06-08 2024-07-03 Tactogen Inc. Advantageous benzofuran compositions for mental disorders or enhancement
TW202216676A (zh) 2020-07-06 2022-05-01 美商塔朵根公司 用於心理疾病或心理強化的有益苯并噻吩組合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268960A (en) * 1969-09-18 1972-03-29 Sandoz Ltd Indole derivatives
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
EP0025331B1 (en) * 1979-09-06 1983-03-02 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3070865D1 (en) * 1979-11-15 1985-08-14 Beecham Group Plc Secondary ethanol amines, their preparation and their use in pharmaceutical compositions
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
GR75101B (da) * 1980-10-23 1984-07-13 Pfizer
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
FR2523964B1 (fr) * 1982-03-23 1985-09-27 Sanofi Sa Nouveaux derives de la tryptamine actifs notamment sur le systeme cardiovasculaire et procede pour leur preparation
JPS60202872A (ja) * 1984-03-27 1985-10-14 Kaken Pharmaceut Co Ltd ベンゾフラン誘導体、その製法およびそれを有効成分とする降圧剤
US4882433A (en) * 1985-10-30 1989-11-21 The Upjohn Company 3'-pyridinylalkylinden- and 3'-pyridinylalkylindol-2-carboxylic acids and analogs
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4886814A (en) * 1986-03-13 1989-12-12 Dr. Karl Thomas Gmbh Substituted thiazoles and oxazoles and 2-hydroxy-morpholines
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB8925032D0 (en) * 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
US5106867A (en) * 1990-05-04 1992-04-21 American Cyanamid Company Method of increasing lean meat in edible animals
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd ２−アルキルアミノ−１−フェニルエタノール誘導体

Also Published As

Publication number Publication date
AU675536B2 (en) 1997-02-06
FI942791A0 (fi) 1994-06-13
CA2164009A1 (en) 1994-12-22
ZA944139B (en) 1995-12-13
NZ265692A (en) 1997-02-24
IL109904A0 (en) 1994-10-07
DE69404039D1 (de) 1997-08-07
NO955047D0 (no) 1995-12-13
BR9406823A (pt) 1996-03-26
CZ327795A3 (en) 1996-08-14
CN1129443A (zh) 1996-08-21
AU6687094A (en) 1995-01-03
ES2104383T3 (es) 1997-10-01
EP0703911B1 (en) 1997-07-02
GR3024134T3 (en) 1997-10-31
HU9401761D0 (en) 1994-09-28
WO1994029290A1 (en) 1994-12-22
PL312005A1 (en) 1996-04-01
HUT70844A (en) 1995-11-28
JPH08506348A (ja) 1996-07-09
US5767133A (en) 1998-06-16
KR960703120A (ko) 1996-06-19
FI942791L (fi) 1994-12-15
ATE154935T1 (de) 1997-07-15
NO955047L (no) 1995-12-13
FI942791A7 (fi) 1994-12-15
EP0703911A1 (en) 1996-04-03
DE69404039T2 (de) 1997-10-16

Similar Documents

Publication Publication Date Title
NO955047D0 (no) Sekundære aminer som antidiabetiske og antifedme-midler
MX9702601A (es) AGONISTAS beta-ADRENERGICOS HETEROCICLICOS.
BR9407239A (pt) Azadioxacicloalquenos substituídos
NO952321D0 (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
TW263499B (da)
FR2681784B1 (fr) Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides.
NO972623D0 (no) Framasöytisk blanding omfattende lamotrigin
ES2131528T3 (es) Nuevos polipeptidos y su uso.
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
IL108288A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
IL107520A0 (en) Substituted ortho-ethenylphenylacetic acid derivatives and pharmaceutical compositions containing them
TW261605B (da)
DE69109293D1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
DE59409923D1 (de) Substituierte aminoalkylaminopyridine
IL112605A0 (en) Mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
FR2700116B1 (fr) Application d'anticonvulsivants comme radioprotecteurs.
ZA939227B (en) Novel triazoloquinazolines,their preparation and use